Cantargia
1,923
SEK
-35,47 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1.314 investorer følger denne virksomhed
cantargia.com
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
CANTA
Daglig lav / høj pris
1,883 / 2,08
SEK
Markedsværdi
353,23 mio. SEK
Aktieomsætning
4,69 mio. SEK
Volumen
2,4 mio.
Seneste videoer
Finanskalender
Delårsrapport
15.11.2024
Ekstraordinær generalforsamling
02.12.2024
Årsrapport
21.02.2025
Delårsrapport
13.05.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Fjärde AP-fonden | 9,9 % | 9,9 % |
Första AP-Fonden | 7,1 % | 7,1 % |
Alecta Pensionsförsäkring, Ömsesidigt | 7,0 % | 7,0 % |
Six Sis AG | 4,7 % | 4,7 % |
Försäkringsaktiebolaget, Avanza Pension | 4,4 % | 4,4 % |
Goldman Sachs International | 3,4 % | 3,4 % |
Handelsbanken fonder | 3,2 % | 3,2 % |
Swedbank Robur Fonder | 2,0 % | 2,0 % |
Brushamn Invest | 1,2 % | 1,2 % |
Prioritet Finans | 1,1 % | 1,1 % |
ViserAlle indholdstyper
Cantargia, Audiocast with teleconference, Q3'24
Notice of extraordinary general meeting in Cantargia AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools